Huang Chen-Yang (Steve Rozen’s Team)
Chen-Yang’s research interest is in Cancer genomics, bioinformatics, thoracic oncology, immuno-oncology, general oncology.
Email: e0470761@u.duke.nus.edu
Publications:
- Chen CB, Wu MY, Ng CY, Lu CW, Wu J, Kao PH, Yang CK, Peng MT, Huang CY, Chang WC, Hui CY, Yang CH, Yang SF, Chung WH, Su SC. Severe Cutaneous Adverse Reactions Induced By Targeted Anticancer Therapies And Immunotherapies. Cancer Management and Research 2018:10 1259–1273
- Chou WC, Lee CL, Yang TS, Huang CY, et al. Changes in serum α-fetoprotein level predicts treatment response and survival in hepatocellular carcinoma patients and literature review. J Formos Med Assoc. 2018 Feb;117(2):153-163.
- Huang CY, Chen BH, Chou WC, Yang CT, Chang JW. Factors associated with the prognosis and long-term survival of patients with metastatic lung adenocarcinoma: a retrospective analysis. J Thorac Dis 2018;10(4):2070-2078.
- Huang CY, Chen TC, Huang SW, et al. Epstein–Barr virus (EBV) associated lymphoepithelioma-like cholangiocarcinoma with elevated EBV DNA titer and treated with systemic chemotherapy. Journal of Cancer Research and Practice. Volume 4, Issue 1, March 2017, Pages 19–22
- Huang CY, Lu CH, Yang CK, et al. A Simple Risk Model to Predict Survival in Patients With Carcinoma of Unknown Primary Origin. Medicine (Baltimore). 2015 Nov;94(47):e2135.